How Ebglyss Performs in Moderate Eczema Trials
Ebglyss (lebrikizumab-lbkz), an IL-13 inhibitor from Eli Lilly, showed strong results in phase 3 trials for moderate-to-severe atopic dermatitis (eczema) in adults and adolescents. In the ADvocate1 and ADvocate2 studies, 43% of patients on Ebglyss achieved clear or almost clear skin (IGA 0/1) at week 16, compared to 13-16% on placebo. EASI-75 (75% improvement in eczema area and severity) was reached by 59% versus 12-18% on placebo.[1][2]
For moderate cases specifically, data from pooled analyses indicate consistent efficacy, with response rates scaling down slightly from severe subgroups but still outperforming placebo by 25-30 percentage points on key measures like IGA and EASI.[3]
What Response Rates Look Like Over Time
Week 16 marks the primary endpoint, but benefits build quickly: 33% hit IGA 0/1 by week 4. Maintenance dosing every 2 weeks (after initial loading) sustains 80-85% response rates through 52 weeks in long-term extensions, with many patients dropping to dosing every 4 weeks.[1][4]
Real-world use early post-approval (FDA nod in September 2024) aligns with trials, though long-term moderate-specific data is emerging.
How It Stacks Up Against Dupixent and Other Biologics
| Treatment | IGA 0/1 at Week 16 (vs placebo) | EASI-75 at Week 16 (vs placebo) | Dosing Frequency |
|-----------|---------------------------------|---------------------------------|------------------|
| Ebglyss | 43% (vs 13-16%) | 59% (vs 12-18%) | Q2-Q4 weeks |
| Dupixent | 36-39% (vs 10-12%) | 44-51% (vs 12-15%) | Q2-Q4 weeks |
| Adbry | 33-36% (vs 13%) | 46-61% (vs 13%) | Weekly |
| Cibinqo | 31% (vs 7%) | 52% (vs 13%) | Daily oral |
Ebglyss edges Dupixent slightly on speed and itch relief (59% EASI-75 vs 44-51%), with fewer injection-site reactions (3% vs 10-15%). It targets IL-13 alone, potentially suiting patients failing broader IL-4/13 blockers.[1][5][6]
Who Responds Best and Who Might Not
Best in patients with high baseline IgE or prior biologic failure—59% EASI-75 in those groups. Adolescents (12+) mirror adult results (41% IGA 0/1). Lower response in Black patients (33% IGA vs 45% overall), per subgroup data, prompting diversity-focused studies.[3][7]
Non-responders (about 40%) often have severe baseline disease or comorbidities like asthma.
Common Side Effects Patients Report
Mild: conjunctivitis (7-10%), herpes infections (3-5%), injection reactions (2-3%). No black-box warnings; discontinuation rate under 2% in trials. Eye issues resolve off-drug for most, less frequent than Dupixent.[1][2]
Cost and Access for Moderate Eczema
List price ~$5,500/month, but copay cards cap at $0-25 for commercials. Covered by most insurers for moderate-to-severe after topicals fail. No patents listed on DrugPatentWatch.com yet for Ebglyss, as it's newly approved—generics unlikely before 2038.8
[1]: Lilly ADvocate1/2 top-line results, NEJM 2023
[2]: FDA Ebglyss label, 2024
[3]: Pooled phase 3 analysis, JAAD 2024
[4]: ADjoin long-term extension, EADV 2024
[5]: Dupixent SOLO1/2 trials, Lancet 2016
[6]: Adbry trials, JAAD 2020
[7]: Ebglyss adolescent study, PID 2024
[8]: GoodRx pricing data, Oct 2024